New therapeutic options, including small inhibitors of somatic mutations commonly found in AML, such as FLT3 or isocitrate dehydrogenase (IDH) inhibitors, have been approved recently for relapsing or refractory (RR) patients. Here, FLT3 is linked to acute myeloid leukemia.